Vaccine Progress, Stock Prices, and the Value of Ending the Pandemic
Viral V. Acharya, Timothy Johnson, Suresh Sundaresan, Steven Zheng
Management Science · 2025 · Volume 71 · Issue 3
Abstract
One measure of the ex ante cost of disasters is the welfare gain from shortening their expected duration. We introduce a stochastic clock into a standard disaster model that summarizes information about progress (positive or negative) toward disaster resolution. We show that the stock market response to duration news is essentially a sufficient statistic to identify the welfare gain to interventions that alter the state. Using information on clinical trial progress during 2020, we build contemporaneous forecasts of the time to vaccine deployment, which provide a measure of the anticipated length of the COVID-19 pandemic. The model can thus be calibrated from market reactions to vaccine news, which we estimate. The estimates imply that ending the pandemic would have been worth from 5% to 15% of total wealth as the expected duration varied in this period. This paper was accepted by Lukas Schmid, finance. Supplemental Material: The online appendix and data files are available at https://doi.org/10.1287/mnsc.2023.00863 .
Keywords
COVID-19, welfare costs, stock prices, vaccine development, regime-switching
Enable JavaScript for citation tools and additional paper interactions.